Table 1 TKI agents under clinical investigation for the treatment of GC
Name or ID | Targets | Phase | NCT identifier |
|---|---|---|---|
Lenvatinib | VEGFR1-3 PDGFRα FGFR KIT RET | Phase II | NCT03321630 |
Erdafitinib or JNJ-42,756,493 | Pan-FGFR | Phase II | NCT02699606 |
Cabozantinib | MET RET AXL VEGFR1-3 FLT3 c-KIT | Phase I/II | NCT03539822 |
KBP-5209 | Pan-EGFR | Phase I | NCT02442414 |
Regorafenib | VEGFR1-3 TIE2 PDGFR-β FGFR KIT RET RAF | Phase III | NCT04879368 |